Cosmos Health Inc. (NASDAQ: COSM) has filed a patent application for a potential treatment for multiple sclerosis (MS), leveraging its AI-powered Cloudscreen drug repurposing platform. This move marks a significant advancement in the company’s intellectual property strategy, utilizing AI-driven simulations and experimental validation to identify a novel mechanism of action for a repurposed marketed drug.
Developed in collaboration with Cloudpharm and the National Hellenic Research Foundation, with support from NLO’s pharma patent experts, the patent — filed under Application Number N2039644 — underscores Cosmos Health’s commitment to using AI in drug discovery. CEO Greg Siokas underlined that this filing reflects the company’s focus on addressing critical medical needs and delivering innovative solutions for complex diseases.
The announcement comes amid growing concerns about multiple sclerosis, a chronic autoimmune disorder affecting 2.9 million people globally. With unpredictable progression and debilitating symptoms, the disease presents an ongoing challenge for patients and healthcare providers. The global MS treatment market, valued at $25.94 billion in 2023, is expected to grow at a 5.9% CAGR through 2030, driven by new therapies and increased healthcare investments.
Cosmos Health’s AI-powered drug repurposing technology is designed to streamline therapeutic discoveries, optimizing treatment pathways for autoimmune diseases. The company’s broader R&D initiatives include AI-driven solutions for obesity, diabetes, and cancer, alongside proprietary pharmaceutical and nutraceutical innovations.
